Is combined treatment with fenofibrate and ezetimibe safe and efficacious in patients with mixed hyperlipidemia?

摘要

The epidemic of obesity and the metabolic syndrome has resulted in a considerable increase in the prevalence of mixed hyperlipidemia over the past decade. Ezetimibe, a cholesterol absorption inhibitor, modestly lowers LDL cholesterol, while fenofibrate, a fibric acid derivative, largely affects triglyceride and HDL cholesterol levels. A combination of ezetimibe and fenofibrate, therefore, could be an effective treatment for mixed hyperlipidemia, especially in patients who are statin intolerant. OBJECTIVE To establish whether long-term coadministered fenofibrate plus ezetimibe is safe and efficacious in patients with mixed hyperlipidemia.